Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neoadjuvant Chemotherapy (NAC) Clear all
Active, not recruiting No phase listed Observational

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

NCT03568448
View directory record Official record
Conditions
HER2 Negative Breast Cancer
Interventions
Response monitoring (no intervention)
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

NCT06396533
View directory record Official record
Conditions
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

NCT06417190
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Tumor
Interventions
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Drug
Lead sponsor
Leslie Ballas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Completed No phase listed Observational

Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging

NCT02510456
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort, Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Monitoring and Predicting Chemotherapy Response Using DOSI

NCT01217385
View directory record Official record
Conditions
Breast Cancer
Interventions
DOSI
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Irvine, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 25, 2026, 2:22 AM EDT
Terminated Phase 1 Interventional

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

NCT01090128
View directory record Official record
Conditions
Stages II-III Breast Cancer
Interventions
Nanoparticle Albumin Bound Paclitaxel, doxorubicin, cyclophosphamide
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Withdrawn Phase 2 Interventional

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

NCT05177796
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 25, 2026, 2:22 AM EDT
Completed No phase listed Observational Results available

ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer

NCT03785782
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

NCT03289195
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

NCT07762586
View directory record Official record
Conditions
Bladder Cancer
Interventions
Neoadjuvant Therapy, Upfront radical cystectomy
Drug · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

SHAPE Neoadjuvant Chemotherapy Response

NCT04715958
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Interventions
Contrast-Enhanced Ultrasound, Perflutren Lipid Microspheres, Ultrasound
Procedure · Drug
Lead sponsor
Kibo Nam
Other
Eligibility
21 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional

NearWave Optical Molecular Monitoring

NCT06744465
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Carcinoma
Interventions
NearWave monitoring
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

NCT04677816
View directory record Official record
Conditions
Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer
Interventions
Standard of Care Neoadjuvant Chemotherapy (NAC), Vitamin D3, Drug Diary
Drug · Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

EUS-RFA PANCARDINAL-1 Trial

NCT04990609
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant Chemotherapy (NAC)
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

Tc99m Sestamibi Molecular Breast Imaging

NCT02324387
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), Tc99m sestamibi
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting No phase listed Observational

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

NCT04897009
View directory record Official record
Conditions
Invasive Breast Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

NCT01663285
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Neoadjuvant Cisplatin and Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

NCT07226154
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Small RNA sequencing, PRECEPT assay (qRT-PCR validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Recruiting Phase 1 Interventional

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

NCT05412225
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
Diagnostic Test · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 2:22 AM EDT
Completed No phase listed Observational

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

NCT06464341
View directory record Official record
Conditions
Breast Cancer
Interventions
Observational study no intervention
Other
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 25, 2026, 2:22 AM EDT
Terminated Not applicable Interventional Results available

Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy

NCT02145390
View directory record Official record
Conditions
Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
Interventions
Transurethral Resection of the Bladder Tumor & Cystoscopy, Intensity Modulated Radiation Therapy, Expanded Prostate Cancer Index Composite Short Form 12, International Prostate Symptom Score
Procedure · Radiation · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 25, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

NCT06223568
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
Interventions
Docetaxel, Cisplatin, PRGN-2009
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 25, 2026, 2:22 AM EDT